SNIPR Biome
PrivateLast Round
Series B
Aug 7, 2025
Total Funding Raised
$124.87M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
SNIPR Biome is a biotechnology company that develops CRISPR-based medicines designed to treat microbial diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SNIPR Biome Comparables
Compare SNIPR Biome with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Locus Biosciences | 88% | |
| Eligo Bioscience | 88% | |
| TechnoPhage | 77% |
SNIPR Biome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 7, 2025 | ||||
| Debt | Dec 9, 2024 | ||||
| Grant | Apr 22, 2024 | ||||
| Grant | May 27, 2021 | ||||
| Series A | Mar 11, 2019 | ||||
Seed | Jul 1, 2017 |
SNIPR Biome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lundbeck Foundation | Seed, Series A |
| EQT Life Sciences | Series A |
| CARB-X | Grant |
| Lundbeckfonden BioCapital | Series B |
| Gates Foundation | Grant |
| European Investment Bank Group | Debt |
| Cystic Fibrosis Foundation | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 62% MoM, reaching 1.5K.
- Sep 15, 2025
Developing a phage cocktail to treat Pseudomonas infections.
Recent news
Latest coverage and updates
- is_developingAug 12, 2026
SNIPR BIOME Aps is developing engineered bacteriophages that selectively eliminate antibiotic-resistant E. coli on Aug 12th '26.
SNIPR Biome Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about SNIPR Biome's valuation, stock price, and market status.
Is SNIPR Biome a public or private company?
SNIPR Biome is a private company.
What is the current stock price of SNIPR Biome?
SNIPR Biome is a private company with no public stock price. No recent secondary market data is available.
How much is SNIPR Biome worth (valuation)?
Valuation information for SNIPR Biome is not publicly available.
Can I buy SNIPR Biome stock?
SNIPR Biome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was SNIPR Biome's last funding round?
SNIPR Biome's most recent funding round was Series B on August 7, 2025.
Who are the main investors in SNIPR Biome?
Key investors in SNIPR Biome include CARB-X, Lundbeckfonden BioCapital, European Investment Bank Group, Wellington Partners.
Will SNIPR Biome IPO soon?
No public IPO plans have been announced for SNIPR Biome.
How can I track SNIPR Biome secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SNIPR Biome's secondary market activity and sign up for updates.